Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

Palatin believes that its existing capital resources will be adequate to fund its currently planned operations, including completing analysis of results of the Company's Phase 2B clinical trial with bremelanotide for FSD, holding an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), and commencing Phase 3 activities, through at least calendar year 2013.

CONFERENCE CALL / WEBCAST
Palatin will host a conference call and webcast on February 14, 2013 at 11:00 a.m. Eastern time to discuss the results of operations and an update on corporate developments in greater detail.  Individuals interested in listening to the conference call live can dial 1-888-539-3678 (domestic) or 1-719-325-2329 (international) pass code 4795478.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 4795478.  The webcast and telephone replay will be available through February 21, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of P
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 New Q4-2014 incentives ... , an industry leading unified communication and collaboration ... agents to deliver cloud-based audio and web/video conferencing ... , With SoundConnect’s Q4 incentive partners ... and/or web conferencing licenses sold, now through December ...
(Date:10/27/2014)... EASTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the "Company"), a worldwide leader in the development ... to the life sciences research market, today announced ... team presented a novel, accurate, highly reproducible, and ... time – routine high-throughput protein analysis on small ...
(Date:10/26/2014)... The report "Data Center Networking ... Equipment, WAN Optimization Appliances]: Global Advancements, Worldwide Forecasts ... center networking market into various segments with an ... also identifies the factors driving this market, various ... with the future roadmaps. , Browse 106 market ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
Breaking Biology Technology:SoundConnect Unveils Q4 Partner Incentives 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... Aug. 1 Medivation, Inc.,(Nasdaq: MDVN ) today ... will present at the BMO Capital Markets 2008 Focus ... Eastern Time at,the Millennium Broadway Hotel in New York., ... and its clinical,development programs for Dimebon for Alzheimer,s and ...
... LITTLE FALLS, N.J., Aug. 1 CANTEL MEDICAL,CORP. ... its Crosstex,International, Inc. subsidiary, effective today. As planned, ... Crosstex, retired effective today,after over 50 years with ... company. Gary Steinberg and Mitchell Steinberg, also,former owners ...
... ROCKVILLE, Md., Aug. 1 Novavax, Inc. (Nasdaq:,NVAX) ... announced,registered direct equity financing of $18 million by ... existing shelf registration statement.,The Company sold 6,686,650 units ... affiliates of the Company. Each unit was comprised,of ...
Cached Biology Technology:Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5 2Cantel Medical Announces Management Succession at Crosstex Healthcare Disposables Subsidiary 2Novavax Announces Closing of $18 Million Registered Direct Offering 2Novavax Announces Closing of $18 Million Registered Direct Offering 3
(Date:10/30/2014)... 2014 Biological membranes are mainly composed of lipid ... solution ions onto lipid membranes helps clarify functional ... provides a quantitative description of the equilibria between ... and Zbigniew Figaszewski from the University of Bialystok, ... these findings, just published in EPJ E ...
(Date:10/29/2014)... to date, researchers have used DNA sequencing to uncover ... Joseph Buxbaum, Ph.D., Icahn School of Medicine at Mount ... of Harvard and MIT, and their colleagues examined more ... unrelated people. They identified changes in 107 genes that ... spectrum disorder (ASD) – a jump from the nine ...
(Date:10/29/2014)... to make their food, but they also need protection from ... a group of molecules in plants that shields them from ... of the American Chemical Society , one team reports on ... Timothy Zwier and colleagues at Purdue University note that the ... serious damage to plant DNA and, as a result, hinder ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2
... model suggests that inhospitable hydrodgen-sulphide rich waters could have ... oceans. The research, published online this week in the ... the oceans 550-700 million years ago and shows that ... of complex life, were controlled by the biological availability ...
... hybrid nanomaterials, i.e. combinations of synthetic polymers and inorganic (gold, ... at the University of Helsinki in April. Part of ... a billionth of a metre, matter and materials behave in ... known what types of effects the nano version of the ...
... 200-plus research universities that make up ScienceWorksForU.S. today again ... across-the-board cuts to discretionary spending that will result in ... The consequences to the U.S. economy of reduced R&D ... reduction in U.S. GDP over the next nine years ...
Cached Biology News:Toxic oceans may have delayed spread of complex life 2Is nanosilver toxic? 2Is nanosilver toxic? 3Sequester will have a devastating impact on america's research enterprise 2Sequester will have a devastating impact on america's research enterprise 3
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
... Tyrosine Hydroxylase (Ser40) Polyclonal Antibody ... against synthetic phosphopeptide corresponding to ... phospho-Ser40 of rat Tyrosine Hydroxylase ... by sequential chromatography on phospho- ...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Biotin anti-human CD164...
Biology Products: